SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
CareDx Announces AlloID and Exclusive Partnership with IDbyDNA
SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 Today,
CareDx, the leading partner in transplant care, and
IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients. The companies will develop and commercialize AlloID, a tailored infectious disease testing solution that identifies more than 100 pathogens and drug resistance in viruses and bacteria, specific to organ transplant donors and recipients.
Transplant recipients take immunosuppression drugs for life to reduce the risk of organ rejection – a major side effect of a dampened immune system is a high risk of infection. Clinicians are constantly balancing therapies to maintain equilibrium and prevent both organ rejection and infection. CareDx, already a leader in multi-modality solutions for trans